Truist Financial
NBIX icon

Truist Financial’s Neurocrine Biosciences NBIX Stock Holding History

Truist Financial’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.03M Buy
17,951
+6,783
+61% +$1.01M ﹤0.01% 1160
2026
Q1 		$1.47M Buy
11,168
+177
+2% +$23.5K ﹤0.01% 1492
2025
Q4 		$1.56M Sell
10,991
-24,333
-69% -$3.53M ﹤0.01% 1440
2025
Q3 		$4.96M Sell
35,324
-4,677
-12% -$634K 0.01% 889
2025
Q2 		$5.03M Buy
40,001
+4,715
+13% +$541K 0.01% 853
2025
Q1 		$3.9M Sell
35,286
-11,139
-24% -$1.41M 0.01% 929
2024
Q4 		$6.34M Sell
46,425
-167,858
-78% -$20.8M 0.01% 734
2024
Q3 		$24.7M Buy
214,283
+182,737
+579% +$25.1M 0.04% 345
2024
Q2 		$4.34M Sell
31,546
-5,802
-16% -$796K 0.01% 915
2024
Q1 		$5.15M Buy
37,348
+153
+0.4% +$20.9K 0.01% 869
2023
Q4 		$4.9M Buy
37,195
+1,423
+4% +$164K 0.01% 869
2023
Q3 		$4.02M Buy
35,772
+415
+1% +$43.7K 0.01% 918
2023
Q2 		$3.33M Sell
35,357
-6,254
-15% -$611K 0.01% 1013
2023
Q1 		$4.21M Sell
41,611
-727
-2% -$75.7K 0.01% 894
2022
Q4 		$5.06M Sell
42,338
-1,731
-4% -$203K 0.01% 813
2022
Q3 		$4.68M Sell
44,069
-6,210
-12% -$630K 0.01% 820
2022
Q2 		$4.9M Sell
50,279
-10,966
-18% -$1.01M 0.01% 810
2022
Q1 		$5.74M Buy
61,245
+18,226
+42% +$1.54M 0.01% 833
2021
Q4 		$3.66M Sell
43,019
-2,257
-5% -$208K 0.01% 1015
2021
Q3 		$4.34M Buy
45,276
+1,771
+4% +$167K 0.01% 937
2021
Q2 		$4.23M Sell
43,505
-2,364
-5% -$227K 0.01% 951
2021
Q1 		$4.46M Buy
45,869
+1,925
+4% +$202K 0.01% 885
2020
Q4 		$4.21M Sell
43,944
-594
-1% -$57.4K 0.01% 867
2020
Q3 		$4.28M Buy
44,538
+3,172
+8% +$367K 0.01% 783
2020
Q2 		$5.05M Buy
41,366
+563
+1% +$62.2K 0.01% 723
2020
Q1 		$3.53M Buy
40,803
+6,005
+17% +$588K 0.01% 769
2019
Q4 		$3.74M Buy
+34,798
New +$3.64M 0.01% 862

Other funds holding NBIX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return
SCP
Seizert Capital Partners Birmingham, Michigan $2.42B AUM 22.12% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Truist Financial's NBIX Position: Q2 2026 in Review

Truist Financial increased its Neurocrine Biosciences (NBIX) stake by 61% in Q2 2026, buying an estimated $1.01M and bringing the position to 17,951 shares worth $3.03M. The position accounts for ﹤0.01% of the portfolio, ranked #1160.

Truist Financial first reported a position in NBIX in Q4 2019 and has held it in 27 quarters since. The position peaked at $24.7M in Q3 2024. 337 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Truist Financial held 17,951 shares of Neurocrine Biosciences worth $3.03M as of Q2 2026.
  • Truist Financial bought 6,783 Neurocrine Biosciences shares in Q2 2026, an estimated $1.01M.
  • Neurocrine Biosciences made up ﹤0.01% of Truist Financial's portfolio in Q2 2026, its #1160 holding.
  • Truist Financial first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 27 quarters since.
  • Truist Financial's Neurocrine Biosciences position peaked at $24.7M in Q3 2024.
  • 337 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.